Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia

BMC Pregnancy and Childbirth

Junko Yasuoka⁴  Masamine Jimba⁴  Kenichi Komada¹  Shinsuke Miyano¹  Gardner Syakantu²  Charles Yekha Msiska³  Henry Kapyata³  Naoko Ishikawa¹  Mable Chirwa³  Sumiyo Okawa⁴ 

[1] National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku 162-8655, Tokyo, Japan;Ministry of Health, Lusaka, Zambia;Ministry of Health Zambia-Japan International Cooperation Agency SHIMA project, Lusaka, Zambia;Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

关键词: Zambia;    Pregnancy;    Adherence;    Antiretroviral (ARV);    Prevention of mother-to-child transmission of HIV (PMTCT);   

Others  :  1228700
DOI  :  10.1186/s12884-015-0697-7

 received in 2015-01-29, accepted in 2015-10-06,  发布年份 2015

【 摘 要 】

Background

Adherence to antiretroviral (ARV) drugs is essential for eliminating new pediatric infections of human immunodeficiency virus (HIV). Since the Zambian government revised the national guidelines based on option A (i.e., maternal zidovudine and infant ARV prophylaxis) of the World Health Organization’s 2010 guidelines, no studies have assessed adherence to ARVs during pregnancy up to the postpartum period. This study aimed to examine adherence to ARVs and identify the associated risk factors.

Methods

A prospective cohort study was conducted in the Chongwe district from June 2011 to January 2014. Self-reported adherence to ARVs was examined during pregnancy and at one week, six weeks, and 24 weeks postpartum among 321 HIV-positive women. The probability of remaining adherent to ARVs was estimated using the Kaplan-Meier method, and the risk factors for non-adherence were identified using the Cox proportional hazard regressions—treating loss to follow-up as non-adherence. The statuses of HIV in HIV-exposed infants were assessed in January 2014.

Results

During the study period, 326 infants were born to HIV-positive women, 262 (80.4 %) underwent HIV testing, and 11 (3.4 %) had their HIV infection detected at the time that they had the latest HIV testing as of January 2014. The ARV adherence rate was 82.5 % during pregnancy, 84.2 % at one week postpartum, 81.5 % at six weeks postpartum, and 70.5 % at 24 weeks postpartum. The probability of remaining adherent to ARVs was 0.61 at day 50, 0.35 at day 100, 0.18 at day 200, and 0.06 at day 300. Attending a referral health center (HC) was a risk factor for non-adherence compared with attending rural HCs that provided HIV care/treatment (adjusted hazard ratio [aHR] 0.71, 95 % confidence interval [CI] 0.57–0.88) and those that did not provide HIV care/treatment (aHR 0.58, 95 % CI 0.46–0.74). A new diagnosis of HIV infection compared to a known HIV-positive status before pregnancy was another risk factor for non-adherence (aHR 1.24, 95 % CI 1.03–1.50).

Conclusions

Maintaining adherence to ARVs through pregnancy to the postpartum period remains a crucial challenge in Zambia. To maximize the treatment benefits, adherence to ARVs and retention in care should be improved at all health facilities.

【 授权许可】

   
2015 Okawa et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]The gap report. UNAIDS, Geneva; 2014.
• [2]Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach: 2010 version. WHO, Geneva; 2010. [http://whqlibdoc. who.int/publications/2010/9789241599818_eng.pdf]
• [3]Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach June 2013. WHO, Geneva; 2013.
• [4]Bartlett JA. Addressing the challenges of adherence. JAIDS. 2002; 29:S2-10.
• [5]Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF et al.. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS. 2012; 26(16):2039-52.
• [6]Kirsten I, Sewangi J, Kunz A, Dugange F, Ziske J, Jordan-Harder B et al.. Adherence to combination prophylaxis for prevention of mother-to-child-transmission of HIV in Tanzania. PLoS One. 2011; 6:e21020.
• [7]Peltzer K, Sikwane E, Majaja M. Factors associated with short-course antiretroviral prophylaxis (dual therapy) adherence for PMTCT in Nkangala district, South Africa. Acta Paediatr. 2011; 100:1253-7.
• [8]Mepham S, Zondi Z, Mbuyazi A, Mkhwanazi N, Newell ML. Challenges in PMTCT antiretroviral adherence in northern KwaZulu-Natal, South Africa. AIDS Care. 2011; 23(6):741-7.
• [9]Ekama S, Herbertson E, Addeh E, Gab-Okafor C, Onwujekwe D, Tayo F et al.. Pattern and determinants of antiretroviral drug adherence among Nigerian pregnant women. Journal of Pregnancy. 2012; 2012:851810.
• [10]Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A. Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother-to-child transmission of HIV in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2013; 16(1):18588.
• [11]Colombini M, Stockl H, Watts C, Zimmerman C, Agamasu E, Mayhew SH. Factors affecting adherence to short-course ARV prophylaxis for preventing mother-to-child transmission of HIV in sub-Saharan Africa: a review and lessons for future elimination. AIDS Care. 2014; 26(7):914-26.
• [12]Kamuyango AA, Hirschhorn LR, Wang W, Jansen P, Hoffman RM. One-year outcomes of women started on antiretroviral therapy during pregnancy before and after the implementation of Option B+ in Malawi: a retrospective chart review. World J AIDS. 2014; 4(3):332-7.
• [13]Ebuy H, Yebyo H, Alemayehu M. Level of adherence and predictors of adherence to the Option B+ PMTCT programme in Tigray, northern Ethiopia. Int J Infect Dis. 2015; 33:123-9.
• [14]Mirkuzie AH, Hinderaker SG, Sisay MM, Moland KM, Morkve O. Current status of medication adherence and infant follow up in the prevention of mother to child HIV transmission programme in Addis Ababa: a cohort study. J Int AIDS Soc. 2011; 14:50. BioMed Central Full Text
• [15]Blacher RJ, Muiruri P, Njobvu L, Mutsotso W, Potter D, Ong’ech J et al.. How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia. AIDS Care. 2010; 22:1323-31.
• [16]Manzi M, Zachariah R, Teck R, Buhendwa L, Kazima J, Bakali E et al.. High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting. Trop Med Int Health. 2005; 10:1242-50.
• [17]Shargie MB, Eek F, Abaychew A. Prophylactic treatment uptake and compliance with recommended follow up among HIV exposed infants: a retrospective study in Addis Ababa, Ethiopia. BMC Res Notes. 2011; 4:563. BioMed Central Full Text
• [18]Chetty T, Knight S, Giddy J, Crankshaw TL, Butler LM, Newell ML. A retrospective study of Human Immunodeficiency Virus transmission, mortality and loss to follow-up among infants in the first 18 months of life in a prevention of mother-to-child transmission programme in an urban hospital in KwaZulu-Natal, South Africa. BMC Pediatr. 2012; 12:146. BioMed Central Full Text
• [19]Zambia country report: monitoring the declaration of commitment on HIV and AIDS and the Universal Access: biennial report. Ministry of Health, Lusaka; 2014. [http://www. unaids.org/sites/default/files/country/documents/ZMB_narrative_report_2014.pdf]
• [20]2010 National protocol guidelines: integrated prevention of mother-to-child transmission of HIV. Ministry of Health Zambia, Lusaka; 2010.
• [21]Ministry of Health, National AIDS Council Zambia. Zambia country report: monitoring the declaration of commitment on HIV and AIDS and the Universal Access: biennial report. Lusaka: Ministry of Health Zambia; 2012. http://www. unaids.org/sites/default/files/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_ZM_Narrative_Report.pdf webcite
• [22]Stringer JS, Sinkala M, Stout JP, Goldenberg RL, Acosta EP, Chapman V et al.. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. JAIDS. 2003; 32(5):506-13.
• [23]Stringer JSA, Sinkala M, Maclean CC, Levy J, Kankasa C, DeGroot A et al.. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS. 2005; 19(12):1309-15.
• [24]Albrecht S, Semrau K, Kasonde P, Sinkala M, Kankasa C, Vwalika C et al.. Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmission. JAIDS. 2006; 41:114-8.
• [25]Chi BH, Chintu N, Cantrell RA, Kankasa C, Kruse G, Mbewe F et al.. Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission. JAIDS. 2008; 48:220-3.
• [26]Conkling M, Shutes EL, Karita E, Chomba E, Tichacek A, Sinkala M et al.. Couples’ voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study. J Int AIDS Soc. 2010; 13:10. BioMed Central Full Text
• [27]Megazzini KM, Sinkala M, Vermund SH, Redden DT, Krebs DW, Acosta EP et al.. A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia. AIDS. 2010; 24:447-55.
• [28]Stringer EM, Ekouevi DK, Coetzee D, Tih PM, Creek TL, Stinson K et al.. Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA. 2010; 304(3):293-302.
• [29]Laine C, Newschaffer CJ, Zhang DZ, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol. 2000; 95(2):167-73.
• [30]Mandala J, Torpey K, Kasonde P, Kabaso M, Dirks R, Suzuki C et al.. Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers. BMC Public Health. 2009; 9:314. BioMed Central Full Text
• [31]Obermeyer CM, Bott S, Carrieri P, Parsons M, Pulerwitz J, Rutenberg N et al.. HIV testing, treatment and prevention: generic tools for operational research. WHO, Geneva; 2009. [http://www. who.int/hiv/pub/operational/or_generic_tools.pdf]
• [32]Central Statistical Office, Ministry of Health, Tropical Disease Research Center, University of Zambia, Macro International Inc. Zambia Demographic and Health Survey 2007. Maryland: Central Statistical Office and Macro International Inc; 2009. http://www. measuredhs.com/pubs/pdf/FR211/FR211[revised-05-12-2009].pdf webcite
• [33]Adult AIDS Clinical Trials Group. ACTG Self report-III. https://www. fstrf.org/apps/cfmx/apps/common/QOLAdherenceForms/resources/actg/forms/english/ql0756_000_eng_v1_20091217.pdf webcite
• [34]Adult AIDS Clinical Trials Group. Supplemental antepartum adherence questionnaire. https://www. fstrf.org/apps/cfmx/apps/common/QOLAdherenceForms/resources/actg/forms/english/qlw0044.pdf webcite
• [35]Semrau K, Kuhn L, Vwalika C, Kasonde P, Sinkala M, Kankasa C et al.. Women in couples antenatal HIV counseling and testing are not more likely to report adverse social events. AIDS. 2005; 19:603-9.
• [36]Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B et al.. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000; 12:255-66.
• [37]Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, Mugyenyi P et al.. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. JAIDS. 2004; 36(5):1100-2.
• [38]Bardeguez AD, Lindsey JC, Shannon M, Tuomala RE, Cohn SE, Smith E et al.. Adherence to antiretrovirals among US women during and after pregnancy. JAIDS. 2008; 48(4):408-17.
• [39]Hosmer DW, Lemeshow S, May S. Applied survival analysis: regression modeling of time-to-event data. 2nd ed. John Wiley & Sons, Inc, New Jersey; 2008.
• [40]van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ. 1998; 317(7156):433-7.
• [41]Becker S, Mlay R, Schwandt HM, Lyamuya E. Comparing couples’ and individual voluntary counseling and testing for HIV at antenatal clinics in Tanzania: a randomized trial. AIDS Behav. 2010; 14(3):558-66.
• [42]Farquhar C, Kiarie JN, Richardson BA, Kabura MN, John FN, Nduati RW et al.. Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. JAIDS. 2004; 37:1620-6.
• [43]Msuya SE, Mbizvo EM, Hussain A, Uriyo J, Sam NE, Stray-Pedersen B. Low male partner participation in antenatal HIV counselling and testing in northern Tanzania: implications for preventive programs. AIDS Care. 2008; 20(6):700-9.
• [44]Vella V, Govender T, Dlamini S, Taylor M, Moodley I, David V et al.. Retrospective study on the critical factors for retaining patients on antiretroviral therapy in KwaZulu-Natal, South Africa. JAIDS. 2010; 55:109-16.
• [45]Kim MH, Ahmed S, Buck WC, Preidis GA, Hosseinipour MC, Bhalakia A et al.. The Tingathe programme: a pilot intervention using community health workers to create a continuum of care in the prevention of mother to child transmission of HIV (PMTCT) cascade of services in Malawi. J Int AIDS Soc. 2012; 15 Suppl 2:17389.
• [46]Okawa S, Chirwa M, Ishikawa N, Pande F, Kapyata H, Msiska C et al.. Operational challenge: Linkages from prevention of mother-to-child transmission services to care and treatment services in Zambia. Proceedings of 20th International AIDS Conference, Melbourne; 2014.
• [47]Murray LK, Semrau K, McCurley E, Thea DM, Scott N, Mwiya M et al.. Barriers to acceptance and adherence of antiretroviral therapy in urban Zambian women: a qualitative study. AIDS Care. 2009; 21:78-86.
• [48]Barigye H, Levin J, Maher D, Tindiwegi G, Atuhumuza E, Nakibinge S et al.. Operational evaluation of a service for prevention of mother-to-child transmission of HIV in rural Uganda: barriers to uptake of single-dose nevirapine and the role of birth reporting. Trop Med Int Health. 2010; 15:1163-71.
• [49]Bunnell R, Opio A, Musinguzi J, Kirungi W, Ekwaru P, Mishra V et al.. HIV transmission risk behavior among HIV-infected adults in Uganda: results of a nationally representative survey. AIDS. 2008; 22(5):617-24.